Incidence of drug-related adverse events related to the use of high-alert drugs: A systematic review of randomized controlled trials

被引:0
|
作者
Menezes, Michelle Santos [1 ]
Doria, Grace Anne Azevedo [1 ]
Valenca-Feitosa, Fernanda [2 ]
Pereira, Sylmara Nayara [2 ]
Silvestre, Carina Carvalho [3 ]
de Oliveira, Alfredo Dias [2 ]
Lobo, Iza Maria Fraga [4 ]
Quintans-Junior, Lucindo Jose [5 ,6 ]
机构
[1] Univ Fed Sergipe, Cidade Univ Prof Jose Aloisio Campos, BR-49100000 Jardim Rosa Elze, Sao Cristovao, Brazil
[2] Univ Fed Sergipe, Dept Pharm, Lab Teaching & Res Social Pharm LEPFS, Cidade Univ Prof Jose Aloisio Campos, BR-49100000 Jardim Rosa Elze, Sao Cristovao, Brazil
[3] Univ Fed Juiz de Fora, Governador Valadares Campus,Univ Campus,Rua Jose L, BR-36036900 Juiz de Fora, MG, Brazil
[4] Univ Fed Sergipe, Univ Hosp, R Claudio Batista Palestine, BR-49060676 Aracaju, SE, Brazil
[5] Fed Univ Sergipe DFS UFS, Physiol Dept, Jardim Rosa Elze, Sao Cristovao, Brazil
[6] Univ Fed Sergipe, Lab Neurosci & Pharmacol Tests LANEF, Jardim Rosa Elze, Rua Marechal Rondon S-N, BR-49100000 Jardim Rosa Elze, Sao Cristovao, Brazil
关键词
Patient safety; Medication errors; Hospital; High-alert medication or dangerous drugs; SEVERE APLASTIC-ANEMIA; ANTITHYMOCYTE GLOBULIN; RAPID TRANQUILIZATION; ATRIAL-FIBRILLATION; SKIN NECROSIS; CYCLOSPORINE; HALOPERIDOL; MORTALITY;
D O I
10.1016/j.rcsop.2024.100435
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: High-alert medication (HAM) is more predictable to cause significant harm to the patient, even when used as intended. The damage related to the HAM lead not only suffering to the patient, but also raise the additional costs associated with care. Objective: Evaluate the incidence of drug-related adverse events related to the use of high-alert medications. Methods: It was conducted an active search for information through COCHRANE databases, LILACS, SciELO, SCOPUS, PubMed/MEDLINE and WEB OF SCIENCE. The search strategy included the following terms: "Patient safety", "Medication errors" and "Hospital" and "High Alert Medications" or "Dangerous Drugs" in different combinations. Then two reviewers independently conducted a preliminary evaluation of relevant titles, abstracts and finally full-text. Studies quality was evaluated according to PRISMA declaration. Results: The systematic review evaluated seven articles, which showed that only 11 HAM identified in the literature could have serious events. The most frequently cited were warfarin (22.2%) which progressed from deep vein thrombosis to gangrene, suggesting lower initial doses, followed by cyclophosphamide (22.2%) and cyclosporine (22.2%) which presented invasive fungal infection and death. In addition to these, morphine was compared with its active metabolite (M6G), with M6G causing fewer serious clinical events related to nausea and vomiting, reducing the need for concomitant use of antiemetics. Conclusions: The most reported drug classes in the articles included that were related to incidence of drug-related adverse events in use of high-alert medications: morphine, M6G-glucuronide, haloperidol, promethazine, ivabradine, digoxin, warfarin, ximelagatran, cyclophosphamide, cyclosporine, and ATG. The formulate protocols for the use of these medications, with importance placed on evaluating, among the classes, the medication that causes the least harm.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Polypharmacy and adverse drug-related events
    Everett, WW
    ANNALS OF EMERGENCY MEDICINE, 2003, 41 (02) : 278 - 279
  • [2] Which Adverse Events and Which Drugs Are Implicated in Drug-Related Hospital Admissions? A Systematic Review and Meta-Analysis
    Haerdtlein, Annette
    Debold, Elisabeth
    Rottenkolber, Marietta
    Boehmer, Anna Maria
    Pudritz, Yvonne Marina
    Shahid, Faiza
    Gensichen, Jochen
    Dreischulte, Tobias
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (04)
  • [4] Adverse events in psychotherapy randomized controlled trials: A systematic review
    Klatte, Rahel
    Strauss, Bernhard
    Fluckiger, Christoph
    Rosendahl, Jenny
    PSYCHOTHERAPY RESEARCH, 2025, 35 (01) : 84 - 99
  • [5] Polypharmacy and adverse drug-related events - In reply
    Hohl, CM
    ANNALS OF EMERGENCY MEDICINE, 2003, 41 (02) : 279 - 279
  • [6] Drug-Related Adverse Events of Osteoporosis Therapy
    Khan, Moira
    Cheung, Angela M.
    Khan, Aliya A.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2017, 46 (01) : 181 - +
  • [7] DRUG-RELATED ADVERSE EVENTS IN HOSPITALIZED ADULTS
    BATES, DW
    LEAPE, L
    PETRYCKI, S
    CLINICAL RESEARCH, 1991, 39 (02): : A596 - A596
  • [8] Counting the costs of drug-related adverse events
    White, TJ
    Arakelian, A
    Rho, JP
    PHARMACOECONOMICS, 1999, 15 (05) : 445 - 458
  • [9] Counting the Costs of Drug-Related Adverse Events
    T. Jeffrey White
    Annet Arakelian
    Jay P. Rho
    PharmacoEconomics, 1999, 15 : 445 - 458
  • [10] A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials
    Wang, Yukun
    Kong, Dejiu
    Wang, Chaokun
    Chen, Jing
    Li, Jing
    Liu, Zhiwei
    Li, Xinyang
    Wang, Ziming
    Yao, Ge
    Wang, Xinshuai
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2020, 19